These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 15629226

  • 21. Quinolone resistance among pneumococci: therapeutic and diagnostic implications.
    Low DE.
    Clin Infect Dis; 2004 May 15; 38 Suppl 4():S357-62. PubMed ID: 15127370
    [Abstract] [Full Text] [Related]

  • 22. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN, Sader HS, Stilwell MG, Fritsche TR.
    Diagn Microbiol Infect Dis; 2007 May 15; 58(1):1-7. PubMed ID: 17408904
    [Abstract] [Full Text] [Related]

  • 23. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I, Cars O.
    J Antimicrob Chemother; 2006 Nov 15; 58(5):960-5. PubMed ID: 16936293
    [Abstract] [Full Text] [Related]

  • 24. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
    Firsov AA, Alferova IV, Smirnova MV, Lubenko IY, Portnoy YA, Zinner SH.
    Int J Antimicrob Agents; 2005 May 15; 25(5):409-13. PubMed ID: 15848296
    [Abstract] [Full Text] [Related]

  • 25. Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002).
    Jones RN, Sader HS, Fritsche TR.
    Diagn Microbiol Infect Dis; 2004 Jun 15; 49(2):147-9. PubMed ID: 15183865
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae.
    Schurek KN, Adam HJ, Hoban DJ, Zhanel GG.
    Int J Antimicrob Agents; 2006 Sep 15; 28(3):266-9. PubMed ID: 16904294
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Therapeutic options for pneumococcal pneumonia in Turkey.
    Oncu S, Erdem H, Pahsa A.
    Clin Ther; 2005 Jun 15; 27(6):674-83. PubMed ID: 16117975
    [Abstract] [Full Text] [Related]

  • 31. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA, Du X, Nicolau DP.
    J Antimicrob Chemother; 2006 Sep 15; 58(3):601-9. PubMed ID: 16857688
    [Abstract] [Full Text] [Related]

  • 32. Decline in the prevalence of pandemic clones Spain23F-1 and Spain9V-3 among US fluoroquinolone-resistant Streptococcus pneumoniae TRUST Surveillance isolates since 2001.
    Davies TA, Yee YC, Goldschmidt R, Sahm DF, Evangelista AT.
    Postgrad Med; 2008 Sep 15; 120(3 Suppl 1):39-45. PubMed ID: 18931470
    [Abstract] [Full Text] [Related]

  • 33. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
    Lister PD.
    Postgrad Med; 2008 Sep 15; 120(3 Suppl 1):46-52. PubMed ID: 18931471
    [Abstract] [Full Text] [Related]

  • 34. Comparative antimicrobial activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.
    Garrison MW.
    J Antimicrob Chemother; 2003 Sep 15; 52(3):503-6. PubMed ID: 12917240
    [Abstract] [Full Text] [Related]

  • 35. Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.
    Endimiani A, Brigante G, Bettaccini AA, Luzzaro F, Grossi P, Toniolo AQ.
    BMC Infect Dis; 2005 Nov 24; 5():106. PubMed ID: 16307682
    [Abstract] [Full Text] [Related]

  • 36. Has the licensing of respiratory quinolones for adults and the 7-valent pneumococcal conjugate vaccine (PCV-7) for children had herd effects with respect to antimicrobial non-susceptibility in invasive Streptococcus pneumoniae?
    Fenoll A, Aguilar L, Granizo JJ, Giménez MJ, Aragoneses-Fenoll L, Mendez C, Tarragó D.
    J Antimicrob Chemother; 2008 Dec 24; 62(6):1430-3. PubMed ID: 18819966
    [Abstract] [Full Text] [Related]

  • 37. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data.
    Kowalski RP, Yates KA, Romanowski EG, Karenchak LM, Mah FS, Gordon YJ.
    Ophthalmology; 2005 Nov 24; 112(11):1987. PubMed ID: 16183128
    [Abstract] [Full Text] [Related]

  • 38. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006.
    Adam HJ, Hoban DJ, Gin AS, Zhanel GG.
    Int J Antimicrob Agents; 2009 Jul 24; 34(1):82-5. PubMed ID: 19342204
    [Abstract] [Full Text] [Related]

  • 39. Prevalence of first-step mutants among levofloxacin-susceptible invasive isolates of Streptococcus pneumoniae in the United States.
    Pletz MW, Shergill AP, McGee L, Beall B, Whitney CG, Klugman KP, Active Bacterial Core Surveillance Team.
    Antimicrob Agents Chemother; 2006 Apr 24; 50(4):1561-3. PubMed ID: 16569885
    [Abstract] [Full Text] [Related]

  • 40. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S, Van Heirstraeten L, Lammens C, Chapelle S, Goossens H.
    J Antimicrob Chemother; 2009 May 24; 63(5):886-94. PubMed ID: 19279051
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.